SCHEMBL22253185

SCHEMBL22253185

NC1CCC(=Nc2ncc(Cl)c(-c3cnc4ccc(Br)cn34)n2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 2/20 0.39
FLT3 P36888 6/20 0.36
CCNT1 O60563 1/20 0.35
CDK9 P50750 1/20 0.35
EIF2AK4 Q9P2K8 5/20 0.34
PIK3CA P42336 2/20 0.33
MTOR P42345 2/20 0.33
NRAS P01111 1/20 0.32
IGF1R P08069 4/20 0.32
LCK P06239 1/20 0.32
RET P07949 1/20 0.32
PDGFRB P09619 1/20 0.32
CDK7 P50613 1/20 0.32
BLK P51451 1/20 0.32
IRAK1 P51617 1/20 0.32
CCNH P51946 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.32
CDK2 P24941 1/20 0.31
KCNH2 Q12809 1/20 0.31
MKNK1 Q9BUB5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22252972 0.85 EIF2AK4 (0.41) EIF2AK4
SCHEMBL22252912 0.78 MAP3K14 (0.44) MAP3K14FLT3CDK9EIF2AK4PIK3CA
SCHEMBL22253187 0.78 EIF2AK4 (0.38) FLT3CCNT1CDK9EIF2AK4NRAS
SCHEMBL20455534 0.77 CDK9 (0.59) MAP3K14FLT3CCNT1CDK9IGF1R
SCHEMBL20455533 0.77 CDK9 (0.59) MAP3K14FLT3CCNT1CDK9IGF1R
SCHEMBL20455677 0.77 MAP3K14 (0.40) MAP3K14FLT3CCNT1CDK9EIF2AK4
SCHEMBL22252910 0.76 MEN1 (0.30)
SCHEMBL22252974 0.74 EIF2AK4 (0.51) EIF2AK4
SCHEMBL1613993 0.74 MAP3K14 (0.60) MAP3K14FLT3CDK9EIF2AK4PIK3CA
SCHEMBL22228874 0.74 MAP3K14 (0.49) MAP3K14FLT3CDK9EIF2AK4PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11111245-B2 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-09-07 US disclosed
US-20200231586-A1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2020-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200231586-A1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS CDK2, CDKL1, CDKL2 MAP3K14 85/4885FLT3 282/4885CCNT1 52/4885
US-11111245-B2 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents CDK2, CDKL1, CDKL2 MAP3K14 85/4885FLT3 282/4885CCNT1 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.